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Analyses involving longitudinal and time-to-event data are quite common in 
medical research. The primary goal of such studies to simultaneously study the 
effect of treatment on both the longitudinal covariate and survival.  Often in medical 
research, there are settings in which it is meaningful to consider the existence of a 
fraction of individuals who have little to no risk of experiencing the event of 
interest.  In this thesis, we focus on such settings with two different data structures. 
In early part of the thesis, we focus on the use of a cured fraction survival models 
performed in a population-based cancer registries. The limitations of statistical 
models which embodied the concept of a cured fraction of patients lack flexibility 
for modelling the survival distribution of the uncured group; lead to a not good fit 
when the survival drops rapidly soon after diagnosis and also when the survival is 
too high. In this study, a cure mixture model is enhanced by developing a dynamic 
semi-parametric exponential function with a smoothing parameter. 
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The latter (major) part of the thesis focuses on modelling the longitudinal and the 
survival data in presence of cure fraction jointly.  When there are cured patients in 
the population, the existing methods of joint models would be inappropriate, since 
they do not account for the plateau in the survival function. We introduce a new 
class of joint models in presence of cure fraction. In this joint model, the 
longitudinal  submodel  is a combination of a random mixed effect model and a 
stochastic process. A semi-parametric submodel is also proposed to incorporate the 
true longitudinal trajectories and other baseline time (dependent or independent) 
covariates. This model accounts for the possibility that a subject is cured, for the 
unique nature of the longitudinal data, and is capable to accommodating both zero 
and nonzero cure fractions. We generalize the two submodels to be 
multidimensional to investigate the relationship between the multivariate 
longitudinal and survival data. 
Bayesian approach was applied to the data using a conjugate  and non-conjugate 
prior families to obtain parameter estimates for the proposed models. Gibbs 
sampling scheme is modified for fitting the joint model. Metropolis Hasting and 
Adaptive Rejection Sampling steps are used to update the Markov chain to estimate 
parameter whose full conditional densities can not be sampled efficiently from the 
existing methods, leading us to propose efficient proposal densities. 
The simulation studies demonstrate that the joint modelling method results in 
efficient estimates and good coverage for the population parameters. The analysis of 
cancer patient’s data indicates that when ignoring the association between the 
longitudinal and the survival data would lead to biased estimates for the most 
important parameters. 
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Analisis melibatkan data longitudinal dan masa sehingga suatu peristiwa berlaku 
merupakan analisis yang biasa dilaksanakan dalam penyelidikan perubatan. Dalam 
penyelidikan perubatan terutamanya dalam sesetengah keadaan, kesan rawatan ke 
atas kovariat longitudinal dan mandirian adalah lebih bermakna jika 
dipertimbangkan kewujudan pecahan individu yang sedikit dan tidak berisiko 
terhadap peristiwa yang menjadi tumpuan. Dalam tesis ini, fokus adalah kepada 
keadaan yang sedemikian dengan melibatkan dua struktur data yang berbeza. 
Dalam bahagian awal tesis, fokus adalah terhadap penggunaan model mandirian 
pecahan sembuh ke atas populasi kanser yang berdaftar. Kekangan bagi model 
statistik yang mengambilkira konsep pecahan sembuh pesakit adalah ianya tidak 
begitu anjal untuk memodelkan taburan mandirian bagi kumpulan yang tidak 
sembuh, justeru mengakibatkan ketidakbagusan penyesuaian apabila mandirian 
menurun secara mendadak selepas diagnosa dan jika mandirian terlalu tinggi. Dalam 
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kajian ini, model campuran sembuh diperkasakan dengan membangunkan fungsi 
dinamik separa parametrik eksponen dengan parametrik pelicin. 
Dalam bahagian kemudiannya (utama), tesis ini memfokus kepada pemodelan 
tercantum data longitudinal dan mandirian dengan kehadiran pecahan sembuh. 
Apabila terdapatnya pesakit yang sembuh dalam populasi, keadaan model tercantum 
yang sedia ada tidak bersesuaian disebabkan ianya tidak mengambilkira bahagian 
mendatar dalam fungsi mandirian. Oleh itu, kami memperkenalkan suatu kelas 
model tercantum yang baharu dengan kehadiran pecahan sembuh. Dalam model 
tercantum ini, submodel longitudinal merupakan kombinasi model rawak kesan 
bercampur dan proses stokastik. Submodel separa parametrik disarankan juga 
mengambilkira trakjetori longitudinal yang sebenar dan kovariat (bersandar atau 
merdeka) berdasar masa yang lain. Model ini mengambilkira kemungkinan yang 
subjek akan sembuh, merupakan keunikan data longitudinal dan berupaya 
menangani pecahan sembuh sifar dan bukan sifar. Seterusnya kami mengitlak dua 
submodel ini menjadi multidimensi untuk menyelidik hubungan di antara 
longitudinal multivariat dan data mandirian.  
Pendekatan Bayesian dilaksanakan kepada data menggunakan famili prior konjugat 
dan bukan konjugat untuk memperolehi anggaran parameter bagi model yang 
dicadangkan. Skema pensampelan Gibbs diubahsuai untuk penyesuaian model 
tercantum. Langkah pensampelan penolakan penyesuaian dan Hasting Metropolis 
digunakan untuk mengemaskini rantaian Markov bagi menganggar parameter yang 
ketumpatan bersyarat penuh tidak boleh dicerap secara berkesan menggunakan 
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kaedah yang sedia ada. Ini menyebabkan kami usulkan cadangan ketumpatan 
efisien.  
Kajian simulasi menunjukkkan keputusan kaedah pemodelan tercantum memberikan 
anggaran yang lebih efisien dan libutan yang baik bagi parameter populasi. Analisis 
data pesakit kanser menunjukkan jika diabaikan hubungan di antara cirian 
longitudinal dan data mandirian, ianya akan menghasilkan anggaran yang pincang 
bagi kebanyakan parameter yang penting. 
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CHAPTER 1
INTRODUCTION
1.1 Introduction
Often in applied statistics, after some empirical data have been collected, the purpose
of the analysis is to construct a statistical model. Otherwise; said, we are interested in
situations where the aim is to explain how an outcome, or response, variable of particular
interest is related to a set of explanatory variables, or covariates.
Longitudinal data is, data in the form of repeated measurements on the same unit over
time. Data are routinely collected in this fashion in a broad range of applications,
including agriculture and the life sciences, medical and public health research, and
physical science and engineering. For example, in a medical study, the antibody immune
measures IgG and IgM may be taken at weekly or monthly intervals on patients with
cancer vaccine. The main reason and advantage of longitudinal analysis is to study the
change over time. That is also how longitudinal analysis differs from repeated measures
analysis. In longitudinal analysis, we model both the dependence of the response on the
covariates and the associations among responses. Longitudinal study has the ability to
distinguish the variation in the outcomes across time for an individual from the ones
among the population. To model the random variability in the longitudinal models
with continuous outcomes, Diggle et al. (1994) distinguish among three components of
variability: random effects, serial association and measurement errors.
In many studies, multivariate outcomes are observed and hence multivariate longitudinal
models are necessary. Many studies have discrete outcome variables which renders tra-
1
ditional likelihood-based methods that require the multivariate normality assumptions
and cumbersome with time-varying covariates inapplicable. Three modern analysis ap-
proaches have been developed over the years for the analysis of longitudinal repeated
measures study with discrete outcome variables. They are the marginal model, the
nonlinear mixed effect model, and the transition model.
The scientific questions of interest often involve not only the usual kinds of questions,
such as how the mean response differs across treatments, but also how the change in
mean response over time differs and other issues concerning the relationship between
response and time. Thus, it is necessary to represent the situation in terms of a sta-
tistical model that acknowledges the way in which the data were collected in order to
address these questions. Complementing the models, specialized methods of analysis
are required. For example, longitudinal data modelling is essential to describe both
trend and variation for biological processes, such as growth curves, effects over time
of medical intervention on physiological characteristics, monitoring human exposure to
carcinogens, and so forth.
A promising approach for longitudinal data analysis is to treat their pathways as real-
izations of a smooth stochastic process, see, e.g., Ramsay and Silverman (2005). This
idea originated when researches wanted to describe the effects of certain treatments on
a response trajectory and naturally progressed to the modelling of random curves in-
cluding models for the effects of treatments and covariates on multivariate longitudinal
observations.
In this thesis, we describe an approach for capturing the correlation structure between
multivariate longitudinal responses, leading to the notion of dynamical correlation to
2
